Quantum BioPharma is advancing its lead multiple sclerosis drug candidate, Lucid-MS, toward Phase 2 clinical development after the U.S. Food and Drug Administration cleared its Investigational New Drug application.
Lucid-MS is being developed as a potential treatment aimed at addressing the demyelination associated with multiple sclerosis, rather than primarily suppressing or modifying the immune response.
The candidate is designed to inhibit peptidyl arginine deiminase 2, or PAD2, an enzyme that the company says has been associated with myelin breakdown when overactive. Quantum BioPharma Ltd. (NASDAQ_…
Multiple sclerosis is a chronic disease affecting the central nervous system in which damage to myelin, the protective coating surrounding nerve fibers in the brain and spinal cord, can disrupt communication between the brain and other parts of the body.
The source estimates that approximately 2.9 million people worldwide were living with multiple sclerosis by 2023, up from roughly 2.3 million in 2013 and 2.8 million in 2020.
In the United States, the article cites research estimating that close to 1 million people are living with MS, more than twice some earlier estimates.
Symptoms can include fatigue, impaired vision, numbness, difficulties with balance and coordination, and cognitive changes. Disease progression also varies significantly from patient to patient, creating challenges for treatment and long-term care.
Many currently available MS treatments are classified as disease-modifying therapies and work by suppressing or modifying immune-system activity.
These therapies, including interferons, glatiramer acetate, and monoclonal antibodies, can reduce relapse rates in relapsing forms of MS. However, the source notes continuing unmet need in progressive forms of the disease and states that currently approved treatments do not directly reverse the neurodegeneration responsible for long-term disability. Quantum BioPharma Ltd. (NASDAQ_… Quantum BioPharma Ltd. (NASDAQ_…
Quantum BioPharma is positioning Lucid-MS within an emerging class of approaches focused more directly on neuroprotection and preserving myelin.
Rather than focusing solely on reducing immune activity, Lucid-MS is intended to interfere with mechanisms associated with demyelination itself.
According to Quantum, preclinical animal studies showed that Lucid-MS prevented myelin degradation. Research involving the compound has appeared in peer-reviewed publications including the Journal of Medicinal Chemistry and Proceedings of the National Academy of Sciences.
These preclinical findings do not establish that the drug will be effective in humans, and the Phase 2 program will be an important step in evaluating its potential therapeutic effect in patients with multiple sclerosis.
FDA clearance of the IND allows Quantum BioPharma to proceed with Phase 2 clinical trials, during which investigators can evaluate efficacy in a controlled patient population while continuing to monitor safety.
The development program is entering clinical testing against the backdrop of a substantial global MS therapeutics market.
The source cites Precedence Research estimates placing that market at approximately $34.8 billion in 2025, with projections for significant expansion through 2035. These market figures are third-party estimates rather than Quantum BioPharma financial guidance.
For Quantum, the central question will be whether its preclinical approach to protecting myelin translates into meaningful clinical outcomes in patients.
The FDA’s IND clearance enables the company to begin addressing that question through the next phase of clinical development.
